Aandeel SNNAQ SIENNA BIOPHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Sienna Biopharmaceuticals, Inc.

Aandelen

SNNAQ

US82622H1086

Beurs gesloten - OTC Markets
Andere beurzen
 19:22:47 25-03-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,000001 USD -.--% Intraday-grafiek van Sienna Biopharmaceuticals, Inc. -.--% -.--%
2019 Transcript : Sienna Biopharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03:55 PM
2019 Transcript : Sienna Biopharmaceuticals, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-09-2019 11:00 AM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.
SIENNA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers SNNAQ
  4. Nieuws Sienna Biopharmaceuticals, Inc.
  5. Andere talen